Lv1
70 积分 2024-11-24 加入
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
1天前
待确认
Correspondence - Tranexamic acid for traumatic brain injury
1天前
已关闭
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2天前
已完结
Rewiring cell death and evading repair: Evolution of temozolomide and emerging strategies against resistant glioblastoma
9天前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
1个月前
已完结
Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
1个月前
已完结
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
1个月前
已完结
Olaparib, temozolomide and concomitant radiotherapy for partially or biopsy-only glioblastoma first-line treatment: results from the OLA-TMZ-RTE-01 phase 1 study
1个月前
已完结
Rethinking ovarian cancer III: the past decade and future directions
2个月前
已完结
皖公网安备34019202002308
